European Commission approves Epclusa for all HCV genotypes

European Commission approves Epclusa for all HCV genotypes

The European Commission approved Gilead Science’s marketing authorization application for Epclusa for the treatment of all chronic hepatitis C genotypes, according to a press release from the manufacturer. Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) is an...